European Union - English - EMA (European Medicines Agency)

astrazeneca ab - exenatide - diabetes mellitus, type 2 - drugs used in diabetes - byetta is indicated for treatment of type-2 diabetes mellitus in combination with:metformin;sulphonylureas;thiazolidinediones;metformin and a sulphonylurea;metformin and a thiazolidinedione;in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies. byetta is also indicated as adjunctive therapy to basal insulin with or without metformin and / or pioglitazone in adults who have not achieved adequate glycaemic control with these agents.

Canada - English - Health Canada

astrazeneca canada inc - exenatide - powder for suspension, sustained-release - 2mg - exenatide 2mg - incretin mimetics

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astrazeneca uk ltd - exenatide - solution for injection - 250microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astrazeneca uk ltd - exenatide - solution for injection - 250microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astrazeneca uk ltd - exenatide - powder and solvent for prolonged-release suspension for inj - 2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astrazeneca uk ltd - exenatide - powder and solvent for prolonged-release suspension for inj - 2mg

European Union - English - EMA (European Medicines Agency)

astrazeneca ab - exenatide - diabetes mellitus, type 2 - drugs used in diabetes - bydureon is indicated in adults 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control (see section 4.4, 4.5 and 5.1 for available data on different combinations).bydureon is indicated for treatment of type 2 diabetes mellitus in combination with:metforminsulphonylureathiazolidinedionemetformin and sulphonylureametformin and thiazolidinedionein adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.

Canada - English - Health Canada

astrazeneca canada inc - exenatide - solution - 5mcg - exenatide 5mcg - incretin mimetics

Canada - English - Health Canada

astrazeneca canada inc - exenatide - solution - 10mcg - exenatide 10mcg - incretin mimetics

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - exenatide - solution for injection - 250microgram/1ml